Current research studies of the relationship between miR-181a and breast cancers

doi:10.3969/j.issn.1006-7795.2017.04.008

Abstract

Abstract: MicroRNAs (miRNAs) are highly conserved non-coding single stranded RNAs. miRNAs participate in fundamental biological processes and pathophysiological processes by silencing their target mRNAs expression through binding to their 3' untranslated regions (3'-UTRs). Emerging studies have shown that alterations of miR-181a levels are involved in the initiation, progression and metastasis of human cancers. Some studies have indicated that miR-181a serves as tumor suppressors, and others have revealed the oncogenic roles of miR-181a. A growing number of evidence has linked the pathological role of miR-181a to breast cancer. Here, we specifically summarize the various published data of the links between miR-181a and breast cancers, and to explain the potential clinical application of miR-181a. miR-181a may be used as a clinically diagnostic biomarkers of breast cancer for early stage diagnosis, for evaluation of the chemotherapy sensitivity, and for directing the clinical treatment in patients.

Key words: breast cancer, miR-181a, biomarkers, diagnosis, chemotherapy

CLC Number:

R737.9

Gu Muqing, Yang Chun, Wang Lijuan, Pierre Hardy, Jia Chanwei, Ruan Xiangyan. Current research studies of the relationship between miR-181a and breast cancers[J]. Journal of Capital Medical University, 2017, 38(4): 526-529.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2017.04.008

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2017/V38/I4/526

References

[1] Bartel D P. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116(2): 281-297.
[2] Sun X, Sit A, Feinberg M W. Role of miR-181 family in regulating vascular inflammation and immunity[J]. Trends Cardiovasc Med, 2014, 24(3): 105-112.
[3] Chen G, Zhu W, Shi D, et al. MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2[J]. Oncol Rep, 2010, 23(4): 997-1003.
[4] Gao W, Yu Y, Cao H, et al. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis[J]. Biomed Pharmacother, 2010, 64(6): 399-408.
[5] Parikh A, Lee C, Joseph P, et al. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition[J]. Nat Commun, 2014, 5: 2977.
[6] Niu J, Xue A, Chi Y, et al. Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer[J]. Oncogene, 2016, 35(10): 1302-1313.
[7] Li Y, Kuscu C, Banach A, et al. miR-181a-5p inhibits cancer cell migration and angiogenesis via downregulation of matrix metalloproteinase-14[J]. Cancer Res, 2015, 75(13): 2674-2685.
[8] 张淑群,魏嫒嫒,马一楠,等.uPA在三阴性乳腺癌组织中的表达及临床意义[J].现代肿瘤医学,2014,22(7):1567-1569.
[9] Mahanivong C, Yu J, Huang S. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator[J]. Mol Carcinog, 2007, 46(3): 165-175.
[10] Noh H, Hong S, Dong Z, et al. Impaired microRNA processing facilitates breast cancer cell invasion by upregulating urokinase-type plasminogen activator expression[J]. Genes & Cancer, 2011, 2(2): 140-150.
[11] Wei J L, Li Y C, Ma Z L, et al. miR-181a-5p promotes anoikis by suppressing autophagy during detachment induction in the mammary epithelial cell line MCF10A[J]. Protein & Cell, 2016, 7(4): 305-309.
[12] Taylor M A, Sossey-Alaoui K, Thompson C L, et al. TGF-β upregulates miR-181a expression to promote breast cancer metastasis[J]. J Clin Invest, 2013, 123(1): 150-163.
[13] Wang Y, Yu Y, Tsuyada A, et al. Transforming growth factor-β regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM[J]. Oncogene, 2011, 30(12): 1470-1480.
[14] Bisso A, Faleschini M, Zampa F, et al. Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer[J]. Cell Cycle, 2013, 12(11): 1679-1687.
[15] Banin S, Moyal L, Shieh S, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage[J]. Science, 1998, 281(5383): 1674-1677.
[16] Strotbek M, Schmid S, Sánchez-González I, et al. miR-181 elevates Akt signaling by co-targeting PHLPP2 and INPP4B phosphatases in luminal breast cancer[J]. Int J Cancer, 2017, 140(10): 2310-2320.
[17] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2015 版)[J]. 中国癌症杂志, 2015, 25(9): 692-754.
[18] Cortez M A, Calin G A. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases[J]. Expert Opin Biol Ther, 2009, 9(6): 703-711.
[19] Guo L J, Zhang Q Y. Decreased serum miR-181a is a potential new tool for breast cancer screening[J]. Int J Mol Med, 2012, 30(3): 680-686.
[20] Ferracin M, Lupini L, Salamon I, et al. Absolute quantification of cell-free microRNAs in cancer patients[J]. Oncotarget, 2015, 6(16): 14545-14555.
[21] McDermott A M, Miller N, Wall D, et al. Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer[J]. PLoS One, 2014, 9(1): e87032.
[22] Zhu Y, Wu J, Li S, et al. The function role of miR-181a in chemosensitivity to adriamycin by targeting Bcl-2 in low-invasive breast cancer cells[J]. Cell Physiol Biochem, 2013, 32(5): 1225-1237.
[23] Del Bufalo D, Biroccio A, Trisciuoglio D, et al. Bcl-2 has differing effects on the sensitivity of breast cancer cells depending on the antineoplastic drug used[J]. Eur J Cancer, 2002, 38(18): 2455-2462.
[24] Jiao X, Zhao L, Ma M, et al. miR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2)[J]. Breast Cancer Res Treat, 2013, 139(3): 717-730.
[25] Selever J, Gu G, Lewis M T, et al. Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells[J]. Clin Cancer Res, 2011, 17(20): 6510-6521.
[26] Niu J, Xue A, Chi Y, et al. Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer[J]. Oncogene, 2016, 35(10): 1302-1313.
[27] Foulkes W D, Smith I E, Reis-Filho J S. Triple-negative breast cancer[J]. N Engl J Med, 2010, 363(20): 1938-1948.
[28] Carey L, Winer E, Viale G, et al. Triple-negative breast cancer: disease entity or title of onvenience?[J]. Nat Rev Clin Oncol, 2010, 7(12): 683-692.
[29] 郭晓龙,郑美珠,左文述,等.三阴性乳腺癌靶向治疗的研究前景[J].中华肿瘤防治杂志,2014,21(21):1751-1756.
[30] 杜娟,阮祥燕.三阴乳腺癌的特点及研究进展[J].首都医科大学学报,2015,36(4):578-582.